Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy

被引：0
|
作者：
Cheema, P. [1 ]
Ton, T. [2 ]
Lambert, P. [2 ]
Merritt, D. [3 ]
Morris, S. [3 ]
Shankar, G. [2 ]
Ganti, A. K. [4 ,5 ]
机构：
[1] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Omaha, NE USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TT01.01
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Chang, Gee-Chen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Tseng, Jeng-Sen
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [22] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Gee-Chen Chang
    Tsung-Ying Yang
    Kun-Chieh Chen
    Kuo-Hsuan Hsu
    Yen-Hsiang Huang
    Kang-Yi Su
    Sung-Liang Yu
    Jeng-Sen Tseng
    Scientific Reports, 10
  • [23] Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
    Provencio-Pulla, Mariano
    Campelo, Rosario Garcia
    Azkarate, Aitor
    Calvo, Virginia
    Cobo, Manuel
    Mosquera, Joaquin
    Nadal, Ernest
    Rodriguez-Abreu, Delvys
    Fabregat, Raquel Marse
    Callejo, Ana
    Domine, Manuel
    Juan-Vidal, Oscar
    Garcia-Garcia, Francisco
    Sanchez, Estela
    Romero, Atocha
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis
    Liu, Sangtian
    Liang, Wenhua
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation
    Cheng, Yajie
    Yang, Bin
    Ouyang, Wen
    Jie, Chen
    Zhang, Wei
    Chen, Gang
    Zhang, Junhong
    Yu, Jing
    Xie, Conghua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
    Li, Y.
    Appius, A.
    Pattipaka, T.
    Feyereislova, A.
    Cassidy, A.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2216 - S2216
  • [27] Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study
    Ding, Z-Y.
    Chen, Y-Y.
    Hong, Y.
    Tong, L-P.
    Li, Q.
    Lin, P-P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs
    Chen, Y.
    Lin, H. M.
    Wan, Y.
    Yin, Y.
    Wu, Y.
    Hernandez, L.
    Danes, C.
    Churchill, E. N.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
  • [29] Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
    Haggstrom, D.
    Mhatre, S. K.
    Chen, F.
    Gao, R.
    Carroll, C.
    Patel, R.
    Park, J.
    Descoteaux, A.
    Stokes, M.
    Daniel, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S409 - S409
  • [30] Real-world long-term outcomes of advanced/metastatic NSCLC patients treated with EGFR TKIs in Nottinghamshire
    Lopez-Escola, C.
    Mengoli, K.
    Sheikh, O.
    Karim, S.
    Sadiq, M.
    LUNG CANCER, 2020, 139 : S62 - S62
12345